Insider trades
Lunger John, Chief Officer of Adaptimmune Therapeutics ADAPY, has filed 0 purchases and 14 sales on the open market. The latest trade was on 25/02/20.
Lunger John
Chief Patient Supply Officer
- First filing
- 23/01/04
- Trades
- 21 trades
- Buys / sales
- 0 / 14
- 12-month net buying
- No record
- Last trade
- 25/02/20
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale | 25/01/17 | 25/01/17 | 5,584 sh | $0.58 | $3,238.72 | −42.6% | |
ADAPY | Open-market sale | 25/01/13–25/01/15 | 25/01/15 | 19,542 sh3 trades | $0.58avg. | $11,333.72 | −58.7% |
ADAPY | Open-market sale | 24/01/16–24/01/17 | 24/01/17 | 22,795 sh3 trades | $0.69avg. | $15,834.37 | −54.5% |
ADAPY | Open-market sale | 24/01/11–24/01/12 | 24/01/12 | 9,229 sh2 trades | $0.85avg. | $7,804.56 | −54.0% |
| Open-market sale | 23/08/01 | 23/08/01 | 3,096 sh | $0.91 | $2,817.36 | −39.6% | |
| Open-market sale | 23/01/17 | 23/01/17 | 4,440 sh | $1.86 | $8,258.4 | −37.9% | |
ADAPY | Open-market sale | 23/01/11–23/01/12 | 23/01/12 | 8,816 sh2 trades | $1.73avg. | $15,229.08 | −52.1% |
| Open-market sale | 23/01/04 | 23/01/04 | 1,100 sh | $1.69 | $1,859 | −38.9% |